Hemolytic Uremic Syndrome of Childhood

Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Number of cases that treated and discharged from hospital

Number of cases with residual raised renal chemistry

walaa gamal abd elrazik

Principal investigator

Assiut University

Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.

Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.

Breast Cancer Female

Ketorolac Tromethamine

Normal Saline

Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn

recorded in days beginning post operative day number one

Total narcotic consumption over first 72 hours converted to morphine equivalence

Total surgical drain output over first 72 hours

Any hematoma requiring management in the operating room

Any infection requiring antibiotics, or flap complications requiring management in the operating room

Joey Corkum

Physician

Nova Scotia Health Authority

Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)

Pelvic Radiation Therapy

Radiation-induced Hemorrhagic Cystitis

12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections

Mesenchymal Stromal Cell (MSC) injections

Hématologie et thérapie cellulaire, Hôpital Saint Antoine

Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

Clinical Phase II Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

Decrease of one grade for rectorrhagia or hematuria on the LENT SOMA scale (Late Effects Normal Tissue Task Force -Subjective, Objective, Management, Analytic), 4 months after the first injection of MSCs.

Frequency of drug consumption (analgesic, opiate)

Quality of life evaluated by SF36 questionnaire (short form survey)

Quality of life evaluated by questionnaire Hospital Anxiety and Depression Scale (HADS)

Mean pain intensity evaluated by Visual Analogue Scale (VAS) during the week prior to the visit.

hematuria/dijareja

Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn

Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Najkompletnija baza ljekovitog bilja potpomognuta naukom